NRGN and myeloid sarcoma: Instead, biomarkers reflecting synaptic dysfunction and/or damage (such as neurogranin, synaptosomal-associated protein 25, SNAP-25, and β-synuclein) have been investigated mostly investigated in cerebrospinal fluid (CSF) samples of patients with neurodegenerative diseases [8–12], but are unexplored in MS.